1. Home
  2. PRAX vs GL Comparison

PRAX vs GL Comparison

Compare PRAX & GL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$331.13

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Globe Life Inc.

GL

Globe Life Inc.

HOLD

Current Price

$145.30

Market Cap

10.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
GL
Founded
2015
1900
Country
United States
United States
Employees
N/A
3695
Industry
Biotechnology: Pharmaceutical Preparations
Life Insurance
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
10.7B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PRAX
GL
Price
$331.13
$145.30
Analyst Decision
Strong Buy
Buy
Analyst Count
15
11
Target Price
$572.13
$166.82
AVG Volume (30 Days)
345.8K
412.3K
Earning Date
05-01-2026
04-22-2026
Dividend Yield
N/A
0.74%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$9.74
Revenue Next Year
$6,395.88
$5.59
P/E Ratio
N/A
$10.21
Revenue Growth
N/A
N/A
52 Week Low
$28.79
$111.13
52 Week High
$354.87
$152.71

Technical Indicators

Market Signals
Indicator
PRAX
GL
Relative Strength Index (RSI) 57.17 60.20
Support Level $282.49 $135.08
Resistance Level $327.65 $147.44
Average True Range (ATR) 17.60 2.82
MACD 2.86 1.00
Stochastic Oscillator 81.68 74.12

Price Performance

Historical Comparison
PRAX
GL

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About GL Globe Life Inc.

Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.

Share on Social Networks: